| SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. United States: Wiley, 2008, vol. 112, No 7, p. 1529-1537. ISSN 0008-543X. |
Other formats:
BibTeX
LaTeX
RIS
@article{817666,
author = {Sonneveld, P. and Hájek, Roman and Nagler, A and Spencer, A and Bladé, J and Robak, T and Zhuang, SH and Harousseau, JL and Orlowski, R},
article_location = {United States},
article_number = {7},
keywords = {multiple myeloma;doxorubicin;bortezomib},
language = {eng},
issn = {0008-543X},
journal = {Cancer},
title = {Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.},
volume = {112},
year = {2008}
}
TY - JOUR
ID - 817666
AU - Sonneveld, P. - Hájek, Roman - Nagler, A - Spencer, A - Bladé, J - Robak, T - Zhuang, SH - Harousseau, JL - Orlowski, R
PY - 2008
TI - Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
JF - Cancer
VL - 112
IS - 7
SP - 1529-1537
EP - 1529-1537
PB - Wiley
SN - 0008543X
KW - multiple myeloma;doxorubicin;bortezomib
N2 - Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma. (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients.
ER -
SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. \textit{Cancer}. United States: Wiley, 2008, vol.~112, No~7, p.~1529-1537. ISSN~0008-543X.
|
